Biohaven .(US:BHVN)2020-08-10 16:39Financial Performance - Biohaven reported $9.7 million in net product revenue for Nurtec ODT in Q2 2020[7, 16] - As of June 30, 2020, Biohaven had $263.9 million in cash, including restricted cash[15] - Biohaven secured access to over $700 million in capital[15] - Additional $525 million cash received or immediately available for draw on close of $950 million Sixth Street & RPI financings in August 2020[15] Commercial Success of Nurtec ODT - Nurtec ODT achieved a 52.6% New Brand Rx market share[7, 9, 38] - Nurtec ODT has 83% commercial coverage, representing 141 million covered lives[7, 9, 22, 38] - Nurtec ODT experienced a 22% average weekly TRx volume growth[7, 38] R&D Pipeline and Regulatory Milestones - Biohaven plans to file an sNDA for Migraine prevention in 2H2020, with potential approval in 1H2021[13] - A PMDA meeting is scheduled for Migraine acute/prevention, with a Europe filing planned for 1Q[13] - Filing for Zavegepant (intranasal) for migraine is expected in 4Q, with potential approval in 2022[13]